Analysis Biovica: Capital injection to reach US market
11 Apr 2019
Biovica has raised SEK 60m in a directed share issue to finance the 510(k)-process in the US and to attain reimbursement on key markets. In our view, it improves the outlook to eventually launch DiviTum for clinical use.
Read the full report (Swedish) here.